Portage biotech highlights first patient dosed in precious-01 study of port-3 for the treatment of ny-eso-1 positive solid tumors

- novel platform allows co-targeting of inkt cells and tumor antigens in a single product- trial marks the first milestone in a comprehensive clinical development plan to evaluate inkt agonists to improve outcomes in a variety of solid tumors westport, connecticut--(newsfile corp. - april 8, 2021) - portage biotech inc. (nasdaq: prtg) (cse: pbt.u) ("portage" or...
ATON Ratings Summary
ATON Quant Ranking